DE69940503D1 - Diagnose und behandlung von hepatischen krankheiten - Google Patents

Diagnose und behandlung von hepatischen krankheiten

Info

Publication number
DE69940503D1
DE69940503D1 DE69940503T DE69940503T DE69940503D1 DE 69940503 D1 DE69940503 D1 DE 69940503D1 DE 69940503 T DE69940503 T DE 69940503T DE 69940503 T DE69940503 T DE 69940503T DE 69940503 D1 DE69940503 D1 DE 69940503D1
Authority
DE
Germany
Prior art keywords
disorders
madcam
disorder
compositions
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940503T
Other languages
English (en)
Inventor
Sherman Fong
Kenneth J Hillan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69940503D1 publication Critical patent/DE69940503D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69940503T 1998-05-13 1999-05-12 Diagnose und behandlung von hepatischen krankheiten Expired - Lifetime DE69940503D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7840598A 1998-05-13 1998-05-13
PCT/US1999/010520 WO1999058573A1 (en) 1998-05-13 1999-05-12 Diagnosis and treatment of hepatic disorders

Publications (1)

Publication Number Publication Date
DE69940503D1 true DE69940503D1 (de) 2009-04-16

Family

ID=22143829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940503T Expired - Lifetime DE69940503D1 (de) 1998-05-13 1999-05-12 Diagnose und behandlung von hepatischen krankheiten

Country Status (10)

Country Link
EP (1) EP1078006B1 (de)
JP (2) JP4817494B2 (de)
AT (1) ATE424417T1 (de)
AU (1) AU3986699A (de)
CA (1) CA2330000C (de)
DE (1) DE69940503D1 (de)
DK (1) DK1078006T3 (de)
ES (1) ES2321994T3 (de)
IL (2) IL139129A0 (de)
WO (1) WO1999058573A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117743T2 (de) * 2001-11-05 2006-10-12 Warner-Lambert Co. Llc Screeningverfahren für Modulatoren von Integrinen
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
CA2552523C (en) * 2004-01-09 2019-11-26 Pfizer Inc. Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
EP1904531B1 (de) * 2005-07-08 2010-10-06 Pfizer Limited Madcam-antikörper
SI3326645T1 (sl) * 2010-10-25 2020-09-30 Biogen Ma Inc. Metode za determinacijo razlik v alfa- 4 integrin aktivnosti s korelacijo razlik v SVCAM in/ali SMADCAM nivojih
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP6970975B2 (ja) * 2016-07-20 2021-11-24 国立大学法人京都大学 ＩｇＧ４関連疾患の検査方法
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
US20200392231A1 (en) * 2017-12-06 2020-12-17 Emory University Methods of Managing Hepatic Steatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808367B1 (de) * 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Addressine der schleimhaut und der blutgefässe und ihre verwendung
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor

Also Published As

Publication number Publication date
IL139129A0 (en) 2001-11-25
WO1999058573A1 (en) 1999-11-18
ATE424417T1 (de) 2009-03-15
CA2330000A1 (en) 1999-11-18
JP4817494B2 (ja) 2011-11-16
DK1078006T3 (da) 2009-06-02
EP1078006A1 (de) 2001-02-28
JP2010280659A (ja) 2010-12-16
EP1078006B1 (de) 2009-03-04
ES2321994T3 (es) 2009-06-15
AU3986699A (en) 1999-11-29
CA2330000C (en) 2015-06-23
IL139129A (en) 2006-09-05
JP2002514660A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
Alawieh et al. Identifying the role of complement in triggering neuroinflammation after traumatic brain injury
Postma et al. Long term effects of vincristine on the peripheral nervous system
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
EP1140170A4 (de) Neue substanzen und methoden zur behandlung und diagnose von okularen krankheiten
BR9815357A (pt) Composição farmacêutica, processos de prevenir ou tratar uma doença, de prevenir ou tratar a doença de alzheimer em um paciente, de avaliar a eficácia de um processo de tratamento de alzheimer em um paciente, de monitorar a doença de alzheimer ou a suscetibilidade a esta em um paciente, uso de peptìdeo a * ou um anticorpo deste, composição, e, conjunto de diagnósticos para a monitoração do tratamento da doença de alzheimer
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
Perzborn et al. Rivaroxaban
Kosten Pharmacotherapy of cerebral ischemia in cocaine dependence
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
EA200000848A1 (ru) Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
DE69940503D1 (de) Diagnose und behandlung von hepatischen krankheiten
NO993393D0 (no) Fotokjemoterapeutiske blandinger
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
Claus et al. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
EA200101212A1 (ru) Замещенные полициклические арил- и гетероарилпиразиноны, которые могут использоваться при селективном ингибировании системы свертывания крови
Selby et al. d-cycloserine blunts motor cortex facilitation after intermittent theta burst transcranial magnetic stimulation: A double-blind randomized placebo-controlled crossover study
BRPI0416591A (pt) métodos e reagentes para o tratamento de distúrbios inflamatórios
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
Stanton et al. Diphenylhydantoin protects against hypoxia-induced impairment of hippocampal synaptic transmission
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition